Literature DB >> 2444718

Structural properties and reactivity of N-terminal synthetic peptides of herpes simplex virus type 1 glycoprotein D by using antipeptide antibodies and group VII monoclonal antibodies.

D L Bosch1, H J Geerligs, W J Weijer, M Feijlbrief, G W Welling, S Welling-Wester.   

Abstract

To investigate the contribution of individual amino acids to the antigenicity of the N-terminal region of herpes simplex virus type 1 glycoprotein D, a series of 14 overlapping synthetic peptides within residues 1 to 30 were examined for their reactivity with monoclonal antibody LP14 (a group VII monoclonal antibody; in herpes simplex virus mutants resistant to LP14, arginine 16 is substituted by histidine) and two antipeptide antisera (antipeptide 9-21 and antipeptide 1-23). Maximal binding was achieved with peptides 9-21, 10-30, 9-30, and 8-30 and the chymotryptic fragment 9-17 of peptide 9-21, suggesting that a major antigenic site is located within residues 10 through 17. Lysine 10 was shown to be essential for high reactivity, either by binding directly to the antibody molecule or by stabilizing an ordered structure of the peptide. The importance of ordered structure was demonstrated by a decrease in reactivity after sodium dodecyl sulfate treatment of peptides 9-21 and 8-30.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444718      PMCID: PMC255962     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting.

Authors:  G H Cohen; V J Isola; J Kuhns; P W Berman; R J Eisenberg
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

Review 2.  Strategy and tactics in protein chemistry.

Authors:  B S Hartley
Journal:  Biochem J       Date:  1970-10       Impact factor: 3.857

Review 3.  Chemically defined antiviral vaccines.

Authors:  R Arnon
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

4.  Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition.

Authors:  H L Niman; R A Houghten; L E Walker; R A Reisfeld; I A Wilson; J M Hogle; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

5.  Type-specific delayed hypersensitivity and protective immunity induced by isolated herpes simplex virus glycoprotein.

Authors:  R D Schrier; L I Pizer; J W Moorhead
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

6.  Effect of monoclonal antibodies on limited proteolysis of native glycoprotein gD of herpes simplex virus type 1.

Authors:  R J Eisenberg; D Long; L Pereira; B Hampar; M Zweig; G H Cohen
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

7.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  The amino-acid sequence of the three smallest CNBr peptides from p-hydroxybenzoate hydroxylase from Pseudomonas fluorescens.

Authors:  J M Vereijken; J Hofsteenge; H J Bak; J J Beintema
Journal:  Eur J Biochem       Date:  1980-12

9.  The covalent structure of bovine liver rhodanese. NH2-terminal sequence and partial structural analysis of tryptic peptides from the citraconylated protein.

Authors:  L Weng; J Russell; R L Heinrikson
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

10.  Protective immunization of mice with specific HSV-1 glycoproteins.

Authors:  W L Chan
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

View more
  11 in total

1.  Analogues of peptide 9-21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies.

Authors:  S Welling-Wester; M Feijlbrief; D G Koedijk; J W Drijfhout; W J Weijer; A J Scheffer; G W Welling
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D.

Authors:  H J Geerligs; M Feijlbrief; M Bolk; C A Bos; J W Drijfhout; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM.

Authors:  A V Nicola; M Ponce de Leon; R Xu; W Hou; J C Whitbeck; C Krummenacher; R I Montgomery; P G Spear; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.

Authors:  W J Weijer; J W Drijfhout; H J Geerligs; W Bloemhoff; M Feijlbrief; C A Bos; P Hoogerhout; K E Kerling; T Popken-Boer; K Slopsema
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Fine mapping of antigenic site II of herpes simplex virus glycoprotein D.

Authors:  V J Isola; R J Eisenberg; G R Siebert; C J Heilman; W C Wilcox; G H Cohen
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Immunological properties of an N-terminal fragment of herpes simplex virus type 1 glycoprotein D expressed in Escherichia coli.

Authors:  C H Kocken; H J Geerligs; C A Bos; G Ab; W J Weijer; J W Drijfhout; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  Detection of antibodies against equine herpesvirus types 1 and 4 by using recombinant protein derived from an immunodominant region of glycoprotein B.

Authors:  R Sinclair; M M Binns; E D Chirnside; J A Mumford
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

8.  Expression of herpes simplex virus type 1 glycoprotein D deletion mutants in mammalian cells.

Authors:  G H Cohen; W C Wilcox; D L Sodora; D Long; J Z Levin; R J Eisenberg
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.

Authors:  Kening Wang; Lesia Dropulic; Joel Bozekowski; Harlan L Pietz; Sinthujan Jegaskanda; Kennichi Dowdell; Joshua S Vogel; Doreen Garabedian; Makinna Oestreich; Hanh Nguyen; Mir A Ali; Keith Lumbard; Sally Hunsberger; Jack Reifert; Winston A Haynes; Jaymie R Sawyer; John C Shon; Patrick S Daugherty; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

10.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.